Joan E Robbins

US Patent:

20090291908, Nov 26, 2009

Filed:

Mar 6, 2006

Appl. No.:

11/659068

Inventors:

Shani Waninger - Carlsbad CA, US
Joan Robbins - Woodland CA, US
Ramos Silvestri - San Diego CA, US

Assignee:

Adventrix Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/662
A61K 31/7072
A61K 31/708
A61K 31/675
A61P 31/18
A61P 31/12

US Classification:

514 45, 514120, 514 50, 514 81

Abstract:

This invention provides for a method of synergistically reducing viral load in a patient infected with a virus. The method comprises the oral co-administering an amount of thiophosphonoformic acid and an amount of a nucleoside or nucleotide reverse transcriptase inhibitor in a synergistic combination.

US Patent:

20180169271, Jun 21, 2018

Filed:

Dec 19, 2017

Appl. No.:

15/847612

Inventors:

- Houston TX, US
Brett Ewald - Carlsbad CA, US
Joan M. Robbins - San Diego CA, US

Assignee:

Memgen, LLC - Houston TX
DNAtrix - Houston TX

International Classification:

A61K 48/00
C07K 14/705
C12N 15/86
A61K 38/17
A61K 45/06

Abstract:

Disclosed are replication-competent oncolytic adenoviruses, comprising chimeric human/mouse CD40 ligands. The oncolytic adenoviruses may be replication competent. The chimeric human/mouse CD40 ligand may be MEM40. Also disclosed are methods comprising administering a replication competent oncolytic adenovirus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from a cancer.